MAT-ES-2003538 v1.0 Abril 2021

    1. Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with po- tential antirheumatic activity–I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol 1985;7:7-18.

    2. Drosos A. Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives? Drugs Aging 2003;20(10):723-36.

    3. Case JP. Old and new drugs used in rheumatoid arthri- tis: a historical perspective. Part 2: the newer drugs and drug strategies. Am J Ther 2001;8(3):163-79.

    4. Cush JJ. Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am 2004;30(2):237-55.

    5. Ranganath VK, Furst DE. Disease-modifying antirheu- matic drug use in the elderly rheumatoid arthritis patient. Rheum Dis Clin N Am 2007;33:197-217.

    6. Manna SK, Aggarwal BB. Immunosuppressive lefluno- mide metabolite (A77 1726) blocks TNF-dependent nu- clear factor-kappa B activation and gene expression. J Immunol 1999;162:2095-102.

    7. Fox RI. Mechanism of action of leflunomide in rheuma- toid arthritis. J Rheumatol Suppl 1998;53:20-6.

    8. Ruckermann K, Fairbanks LD, Carrey EA, Hawrylowi- cz CM, Richards DF, Kirschbaum B, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimu- lated T-lymphocytes from healthy humans. J Biol Chem 1998;273(34):21682-91.

    9. Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, Caulfield JP, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhi- biting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995;275:1043-9.

    10. Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999;58(6):1137-64.

    11. Xu X, Blinder L, Shen J, Gong H, Finnegan A, Williams JW, et al. In vivo mechanism by which leflunomide con- trols lymphoproliferative and auto immune disease in MRL/MpJ-Ipr/Ipr mice. J Immunol 1997;159:167-74.

    12. Siva C, Eisen SA, Shepherd R, Cunningham F, Fang MA, Finch W, et al. Leflunomide use during the first 33 months after Food and Drug Administration approval: experience with a national cohort of 3,325 patients. Ar- thritis Rheum 2003;42:745-51.

    13. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002;41:421-30.

    14. Chong AS, Huang W, Liu W, Luo J, Shen J, Xu W, et al. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplanta- tion 1999;68:100-9.

    15. Weinblatt M, Kremer J, Coblyn J, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety, and effi- cacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322-8.

    16. Li J, Yao H, Jin Y, Zhang YF, Li CY, Li YH, et al. Pharma- cokinetics of leflunomide in Chinese healthy volunteers. Acta Pharmacol Sin 2002;23:551-5.

    17. Keen HI, Conaghan PG, Tett SE. Safety evaluation of le- flunomide in rheumatoid arthritis. Expert Opin Drug Saf 2013;12:581-8.

    18. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and metho- trexate. Arch Intern Med 1999;159:2542-50.

    19. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Ol- sen N, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflu- nomide compared with methotrexate. Arthritis Rheum 2001;44:1984-992.

    20. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic pro- gression of rheumatoid arthritis. Results from three randomized controlled trials of leflunomide in pa- tients with active rheumatoid arthritis. Arthritis Rheum 1999;43:495-505 [erratum: Arthritis Rheum 2000;43:1345].

    21. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulophasalazine in active rheumatoid arthritis: a double-blind, randomized, multi- center trial. Lancet 1999;353:259-66.

    22. Scott DL, Smolen JS, Kalden JR, van de Putte LB, Lar- sen A, Kvien TK, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001;60:913-23.

    23. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B, et al. A comparison of the effi- cacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000;39:655-65.

    24. Alcorn N, Saunders S, Madhok R. Benefit-risk as- sessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009;32:1123-34.

    25. van Riel PL, Smolen JS, Emery P, et al. Leflunomide: a manageable safety profile. J Rheumatol Suppl 2004;71: 21-24.

    26. Van Roon EN, Jansen TL, Houtman NM, Spoelstra P, Brouwers JR. Leflunomide for the treatment of rheuma- toid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf 2004;27:345-52.

    27. Cassina M, Johnson DL, Robinson LK, Braddock SR, Xu R, Jimenez JL, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Ar- thritis Rheum 2012;64:2085-94.

    28. Sevilla-Mantilla C, Ortega L, Agúndez JA, Fernández- Gutiérrez B, Ladero JM, Díaz-Rubio M. Leflunomide induced acute hepatitis. Dig Liver Dis 2004;36(1):82-4.

    29. Takeishi M, Akiyama Y, Akiba H, Adachi D, Hirano M, Mimura T. Leflunomide-induced acute interstitial pneu- monia. J Rheumatol 2005;32:1160-3.

    30. Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Ar- thritis Rheum 2006;54:1435-9.

    31. Smolen JS, Landewe R, Bijlsma J, Burmester G, Cha- tzidionysiou K, Dougados M, et al. EULAR recommen- dations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antir- heumatic drugs: 2016 update. Ann Rheum Dis 2017; 76(6):960-77.

    32. Osiri M, Shea B, Welch V, Suarez-Almazor ME, Strand V, Tugwell P, et al. Leflunomide for the treatment of rheu- matoid arthritis. Cochrane Database Syst Rev 2003;(1): CD002047.

    33. Amit M, Rakhee M. A comparative 3-year clinical study of combined leflunomide and methotrexate vs metho- trexate alone as DMARD in rheumatoid arthritis. The Journal of Rheumatology 2006;9 Suppl 1:A190.

    34. Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, et al. Combination leflunomide and metho- trexate therapy for patients with active rheumatoid ar- thritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol 2004;31:1521-31.

    35. Lao ZY, Ni LQ, Zhang ZF, Zhou JL, Chen L, Zhang F, et al. Leflunomide in treating rheumatoid arthritis: a double-blind study. Chinese Journal of New Drugs and Clinical Remedies 2001;20:94-7.

    36. Amit M. A comparative 2-year clinical study of combi- ned leflunomide and methotrexate vs methotrexate alo- ne as DMARD in rheumatoid arthritis. Abstract book, the 11th APLAR meeting, Jeju, South Korea. Seoul, Sep 2004:2093.

    37. Antony T, Jose VM, Paul BJ, Thomas T. Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis. Indian J Med Sci 2006;60:318-26.

    38. Dougados M, Emery P, Lemmel EM, de la Serna R, Zer- bini CA, Brin S, et al. Efficacy and safety of leflunomide and predisposing factors for treatment response in pa- tients with active rheumatoid arthritis: RELIEF 6-month data. J Rheumatol 2003;30:2572-9.

    39. Wislowska M, Jakubicz D. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF- alpha blocker plus methotrexate versus methotrexate or leflunomide alone. Rheumatol Int 2007;27: 641-7.

    40. Mariette X, Bijlsma JWJ, Herold M, Eiselstein J, Spen- cer-Green GT, Kupper H. Efficacy evaluation of adalimu- mab (Humira®) in combination with single and multiple disease modifying antirheumatic drugs in the REACT trial. Annals of the Rheumatic Diseases 2004;63 Suppl 1:278.

    41. Finckh A, Dehler S, Gabay C. The effectiveness of leflu- nomide as a co-therapy of tumour necrosis factor inhi- bitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis 2009;68(1):33-9.

    42. De Stefano R, Frati E, Nargi F, Baldi C, Menza L, Ham- moud M, et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti- TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol [Internet] 2010;29(5):517-24.

    43. Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination

Temas relacionados:

Actualidad Científica

Artritis Reumatoide

Actualiza tus conocimento sobre la Artritis Reumatoide